About BioPlx
BioPlx was a Healthcare company based in Kanpur (India) founded in 2016 by Ravi Starzl. It delivers comprehensive non-antibiotic solutions for infectious disease control. It operates on a B2B model. BioPlx has raised $2.72 million across 2 funding rounds. Its chief executive is Ravi Starzl. The company is recorded as dissolved. Its focus areas include Biotechnology, Infectious Disease Control and Non-Antibiotic Methods. Its legal entity in India is Bioplx Microbiomics Pvt. Ltd (U73200UP2016FTC086076). Its competitors include Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group and 5 more; 7 of its 10 listed competitors have raised funding.
Company details
BioPlx, established in 2016 and currently in Dissolved stage, focuses on providing healthcare solutions, advancing biotech innovations, infectious disease control, and non-antibiotic methods. Delivers comprehensive non-antibiotic solutions for infectious disease control. Adapting to market demands with innovation and client-focused strategies.
- Headquarters Kanpur, India
- Founders Ravi Starzl
- SectorsHealthcare
- Website bioplx.com
- Legal Name Bioplx Microbiomics Pvt. Ltd.
- Date of Incorporation 01 Sep, 2016
- Jurisdiction Meerut, Uttar Pradesh, India
- Net Loss-₹6 Lakh
FY 2023 · 0% margin
- EBITDA-₹5.3 Lakh
FY 2023 · 0% margin
- Total Equity Funding$2.72M (USD)
in 2 rounds
- Latest Funding Round$1.08M (USD), Seed
Feb 2020
Associated legal entities of BioPlx
BioPlx operates through Bioplx Microbiomics Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2023) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Bioplx Microbiomics Private Limited CIN U73200UP2016FTC086076 | Active | 01 Sep 2016 | Meerut, Uttar Pradesh | – | – | 3 | View details |
Funding Insights of BioPlx
BioPlx has successfully raised a total of $2.72M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $1.08 million completed in February 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $2.72M
- Total Rounds 2
- Last Round Seed — $1.08M
- First Round $1.64M
(Aug 2019)
All 2 funding rounds of BioPlx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2020 | $1.08M | Seed | – | – | – |
| Aug 2019 | $1.64M | Seed | – | – | – |
Board of directors of Bioplx Microbiomics Private Limited (BioPlx)
Bioplx Microbiomics Private Limited is the primary company behind BioPlx. The board of Bioplx Microbiomics Private Limited currently have 3 directors; the longest-serving is Bimla Starzl, appointed in 2016. 2 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Bimla Starzl DIN 02606947 | Director | 01 Sep 2016 | 10 yrs 1 mo | Bioplx Microbiomics Private Limited |
| Timothy Wakfield Starzl DIN 01785763 | Director | 01 Sep 2016 | 10 yrs 1 mo | Bioplx Microbiomics Private Limited |
| Shilpi Agarwal DIN 07758320 | Director | 03 Mar 2017 | 9 yrs 7 mo | Bioplx Microbiomics Private Limited |
People of BioPlx
1 people are tracked at BioPlx (1 in leadership).
| Name | Role | Group |
|---|---|---|
Ravi Starzl | Co-Founder, CEO | Leadership |
Complete people profiles for BioPlx
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of BioPlx
Figures of Bioplx Microbiomics Private Limited, the primary company behind BioPlx, for FY 2023. Net loss was -₹6 Lakh (0% margin). EBITDA was -₹5.3 Lakh (0% margin).
- -₹6 LakhNet loss · 0% margin
- -₹5.3 LakhEBITDA · 0% margin
- ₹2.60 CrPaid-up capital
Balance sheet, profit and loss, cash flow and ratios of Bioplx Microbiomics Private Limited are on its company page.
Detailed financial statements for BioPlx
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of BioPlx
3 dated milestones of BioPlx across 4 years, from founding to its latest funding, stage changes and deals.
- Founded BioPlx is founded.
- Funding First funding round of $1.6M.
- Funding Latest funding round, Seed, of $1.1M.
Competitors of BioPlx
BioPlx has 10 listed competitors in our database, 7 of them funded. They include Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| univercells.com | 2013 | Charleroi, Belgium | $150.64M | 87 | Biomanufacturing technologies are supplied for biopharma antibody and vaccine production. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform | |
| straumann.com | 1954 | Basel, Switzerland | – | – | Dental implants and regenerative dentistry products are developed. | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. | |
| judges.uk.com | 2002 | London, United Kingdom | – | 622 | Acquisition and development of scientific instrument businesses is conducted. | |
| insmed.com | 1999 | Bridgewater, United States | – | 912 | Developer of small molecule inhibitors for rare lung diseases | |
| savarapharma.com | 2008 | Austin, United States | $67.82M | 37 | Therapeutics for rare respiratory diseases are developed by Savara Pharma. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. |
Detailed competitors of BioPlx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Infectious Diseases
10 companies that operate in the same segment as BioPlx (Infectious Diseases), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 | |
Clinical diagnostics and drug discovery for immune diseases are provided. | 2009 | Seattle, Washington, United States | USD 419.15 M | USD 276.98 M | 619 | |
Vaccines for infectious diseases are developed using cell-free protein synthesis. | 2013 | Foster City, California, United States | USD 347 M | – | 414 | |
Portable PCR diagnostics for infectious diseases are developed. | 2010 | San Jose, California, United States | USD 386.33 M | – | 172 | |
Developing glucan synthase inhibitors for the treatment of fungal infections. | 1999 | Jersey City, New Jersey, United States | USD 62.65 M | USD 20.6 M | 28 | |
Sherlock Biosciences is focused on molecular diagnostics development. | 2019 | Watertown, United States | USD 111 M | – | 33 | |
Provider of diagnostic solutions for systemic infections | 2016 | San Francisco, California, United States | USD 191.47 M | – | 54 | |
Developer of novel protein-based therapeutics using machine learning and biological engineering | 2018 | Somerville, Massachusetts, United States | USD 693 M | – | 329 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Bioplx
Complete news archive for BioPlx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BioPlx
BioPlx was founded in 2016 and raised its 1st funding round 3 years after it was founded.
BioPlx is headquartered in Kanpur, India. It is registered at Kanpur, Uttar Pradesh, India.
Ravi Starzl is the current CEO of BioPlx. They have also founded this company.
BioPlx is a funded company, having raised a total of $2.72M across 2 funding rounds to date. The company's 1st funding round was a Seed of $1.64M, raised on Aug 2019.
BioPlx, established in 2016 and currently in Dissolved stage, focuses on providing healthcare solutions, advancing biotech innovations, infectious disease control, and non-antibiotic methods. Delivers comprehensive non-antibiotic solutions for infectious disease control. Adapting to market demands with innovation and client-focused strategies.
BioPlx's top competitors include Sutro Biopharma, Avidity Biosciences and Antheia.
BioPlx operates through Bioplx Microbiomics Private Limited.
The legal entities of BioPlx currently have 3 directors, including Bimla Starzl, Shilpi Agarwal, Timothy Wakfield Starzl.